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August 2009476 Letters to the editorregistry data in the Discussion section of the article. As a major
point of clarification, this is not an observational cohort study but
rather a real-world patient registry.
With respect to the first issue of complete and unbiased
follow-up, Drs Meier and Hayward are correct in identifying
systematic differences, noting that the Center for Medicare and
Medicaid Services mandates in-hospital results only for carotid
artery stenting (CAS) and not carotid endarterectomy (CEA).
However, the Society for Vascular Surgery (SVS) Vascular Registry
(VR) was designed with this knowledge beforehand, and as a
condition of participation in VR, some centers agreed to enter
both interventions as well as follow-up.
The goal of the article was to report the results of the entire
VR, since it is the first large-scale registry that has available data on
the current practice application of CAS and CEA. Although the VR
does not have predefined visit intervals, it does rely on each
facility’s standards of care to capture the real-world experience,
including follow-up. As noted in the article, in-hospital and 30-day
comparisons were both reported. The in-hospital results were
reported on 100% of patients; and even in this comparison, the
results have shown, in this registry, the superiority of CEA.
With respect to rigorous controls for confounders, there are
several aspects to discuss. It is true that a great deal of selection bias
can be introduced in a real-world setting in which physicians are
allowed to choose which procedure better suits the best interest of
the patient. By definition, patients who receive CAS are going to be
of a higher risk than patients who receive CEA. Thus, because this
is a current clinical practice (real-world experience) registry, diver-
sity in the patient population is expected and cannot have “rigor-
ous control for confounders.” In an effort to adjust for these
confounders, the authors performed logistic regression using back-
wards elimination, as described in the manuscript. It had also been
suggested in another Letter to the Editor that propensity score
matching be used,1 for which the authors had responded that even
with using propensity matching, still CAS patients had worse
30-day outcomes than CEA patients.2
Drs Meier and Hayward also contend that the VR results are in
conflict with several randomized controlled trials (RCTs) compar-
ing CAS and CEA. Although some RCT results conflict with the
VR results, other RCTs, such as Endarterectomy versus Stenting in
Patients with Symptomatic Severe Carotid Stenosis (EVA-3S),3 are
not in disagreement. Rather, 30-day results of EVA-3S show worse
outcomes of CAS (9.6%) vs CEA (3.9%) than that reported from
VR, as do the 4-year results of EVA-3S.4 We would like to reiterate
the conclusion at the end of the article, that “The debate about the
interpretation of the results of this study as well as results of other
CAS studies will continue until randomized trials such as Interna-
tional Carotid Stenting Study (ICSS) in Europe and CREST in
North America are reported.”5
Anton N. Sidawy, MD, MPH
Rebecca J. Shackelton, ScM
Flora S. Siami, MPH
and the SVS Outcomes Committee
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Regarding “Improved outcomes are associated with
multilevel endovascular intervention involving the
tibial vessels compared with isolated tibial
intervention”
It was with great interest that we read the article by Sadek et
al.1 They concluded that patients who undergo multilevel inter-
vention involving the tibial vessels exhibit improved secondary
patency compared with those who undergo intervention for lesions
isolated to the tibial vessels. We wholeheartedly agree with their
opinion as well as their recommendation.
The authors reported that a comparison between single-level
intervention and multilevel intervention involving the infrapopli-
teal vasculature has never been performed. Actually, we first de-
scribed the importance of multilevel endovascular intervention
involving the infrapopliteal vasculature.2 Furthermore, we re-
ported the fact that more than one tibial artery vessel being treated
in the same setting could be an explanation for a better outcome or
improved results.
The aim for performing multilevel endovascular intervention
is to improve the runoff and, therefore, decrease the risk of
restenosis related to the fact that poor runoff was reported as a
variable predicting restenosis. We definitely need to be more
aggressive and treat all reachable lesions to improve clinical out-
comes of endovascular procedures. Multilevel lesions should not
be considered a limitation for an endovascular approach, and on
the contrary, as reported in this article and in our experience,
should prompt us to consider endovascular as a first-line procedure
in patients with critical limb ischemia.
Ludovic Canaud, MD
Pierre Alric, MD, PhD
Department of Vascular and Thoracic Surgery
Hospital A de Villeneuve
Montpellier, France
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Regarding “Open-cell versus closed-cell stent design
differences in blood flow velocities after carotid
stenting”
Although several studies have suggested that stent placement
in the carotid artery alters its biomechanical properties, leading to
an increase in Duplex Ultrasound (DUS) velocities in the absence
of residual stenosis, many uncertainties remain about the general-
izability of these single-center results with small sample sizes.1
Recently, Pierce et al described disproportionately elevated veloc-
ities for closed cell design when comparing different types of
stents.2 Surprisingly, the authors concluded that their results were
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nents. We have a few comments.
From our animal laboratory experience we do agree that
observed velocity alterations seem to be stent type specific.1 Far
more than just free cell area, however, overall stent design and
procedure related properties such as length, sizing, and self-
expandability all influence post-procedural hemodynamic pertur-
bations and velocities, even in the absence of residual stenosis.3
Secondly, concerning the two predominantly used stents,2 the
Wallstent is an example of a Braided Elgiloy Self-Expanding Stent
(BESES) constructed of independent wires. Acculink has a Surface-
Spanning Micro Stent (SSMS) architecture with interconnected
wires, and this, more than free cell area, influences wall apposition
and subsequent alterations in carotid wall mechanics.
Thirdly, stent placement causes a compliance (Cp) mismatch
between the stented part of the artery and its native upstream and
downstream segments. In diseased arteries, the arterial wall con-
tributes to the overall stiffness of the stented site, and this varies
according to the amount of atherosclerosis and calcium load within
the wall. Therefore, final Cp alters to various degrees, which might
explain why DUS velocities are significantly elevated in a percent-
age of patients but not in all.
Fourth, current stents are self-expanding, and their diameters
steadily increase with time (positive arterial remodelling), poten-
tially achieving better expansion of the lumen.4 Serial measure-
ments of stent diameter confirmed continued expansion after
Wallstent deployment, with most marked expansion occurring
during the first three months. Pierce et al aimed to analyze DUS
before and immediately after stenting. However, post-intervention
DUS was obtained in no less than a median five days (range: 1-25
days). This is a serious study limitation, and timing of postoperative
DUS should have been standardized preferentially within 24 hours
and at three months following the procedure. In the meantime,
vascular laboratories should realize that carotid stent placement
itself leads to elevated velocities, which might well be stent type
specific.
Gert J. de Borst, MD, PhD
Frans L. Moll, MD, PhD
University Medical Center Utrecht
Utrecht, The Netherlands
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Reply
We appreciate the astute and thoughtful comments regarding
our study. As outlined, it is certainly clear that many factors
contribute to the elastic modulus and compliance of the carotidartery after stenting, which result in changes in flow hemodynam-
ics. Our data highlights the importance of stent design and its
salient role in demonstrating elevated duplex velocities in the
absence of angiographically demonstrable stenosis after carotid
stenting.
We do agree that the optimal timing of postoperative duplex
ultrasound (DUS) after carotid stenting has not been established,
but we doubt this is a real study limitation. Although initially we
obtained duplex scans within 24 hours after stenting, the timing of
the postoperative DUS was later postponed, primarily as a factor of
study design. Many of the patients in our series were enrolled in
post-marketing registries and clinical trials (eg, SAPPHIRE,
CREST, EMPIRE), all of which require post-intervention DUS at
one month. Because most randomized clinical trials assessing
carotid stenting required postoperative DUS at one and six months
and yearly thereafter, such protocols have been widely adopted in
most centers. We believe that DUS at one month should serve as a
baseline study and that changes in blood flow velocities related to
stent design are validated at this time period. Obtaining DUS at one
and 90 days, as suggested, may be unnecessary, cost-ineffective, and
clinically impractical. Obviously, long-term changes in blood flow
velocities related to stent design and incidence of in-stent restenosis
need to be further investigated. In this regard, we are currently
conducting studies to quantify to what extent stent design differences
in carotid velocities may influence DUS criteria for precisely defining
restenosis after carotid artery stenting.
Damon Scott Pierce, MD
Eric B. Rosero, MD
Carlos H. Timaran, MD
University of Texas Southwestern Medical Center
Dallas, Tex
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Regarding “A randomized trial of cryo stripping
versus conventional stripping of the great
saphenous vein”
It was with great interest that we read the article by Klem et
al,1 describing a trial comparing two methods of stripping of the
great saphenous vein (GSV). They are to be complimented on
having presented a clearly honest and large prospective series on
cryo stripping. However, some comments have to be made.
The first comment is on the primary outcome, residual GSV at
6 months. Although it seems likely that residual GSV will influence
the outcome at long-term, little is known about this phenomenon.
We do know that residual veins after endovascular treatment do
not correlate well with clinically recurrent disease. It is a pity,
therefore, that authors did not mention clinical recurrent disease at
follow-up; this should have given us at least an impression, espe-
cially since both techniques performed the same in the quality of
life scores.
Second, I would like to comment on the technique used. Most
surgeons that use the cryo device freeze much shorter than 10
seconds: 3 to 5 seconds suffice to adhere the vein to the probe, and
in such manner, a much smaller part of the adjacent tissue will
freeze together with the vein. Generally thereafter, the vein may be
extracted after invagination, causing less tissue damage, and en-
abling a second or third passage of the probe in case the vein
ruptures during extraction. Invagination is generally not possible
when the cryo probe is used in the “classic” manner, with a large
block of frozen tissue at the tip. The less subtle stripping, and the
necessity of a cosmetically unwanted and time consuming distal
incision in conventional stripping are the main reasons for using
the cryo probe.
Third, I would like to emphasize the fact that significantly
more of the patients lost for follow-up were in the conventional
